ERAS Erasca, Inc.

Nasdaq erasca.com


$ 2.32 $ -0.07 (-2.94 %)    

Tuesday, 04-Nov-2025 15:59:57 EST
QQQ $ 615.11 $ -4.04 (-0.65 %)
DIA $ 470.25 $ 0.57 (0.12 %)
SPY $ 672.36 $ -0.79 (-0.12 %)
TLT $ 90.13 $ 0.15 (0.17 %)
GLD $ 362.19 $ -1.27 (-0.35 %)
$ 2.31
$ 2.38
$ 2.22 x 600
$ 2.57 x 40
$ 2.22 - $ 2.38
$ 1.01 - $ 3.31
1,449,643
na
655.28M
$ 1.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-27-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-23-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-24-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-26-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 stifel-initiates-coverage-on-erasca-with-buy-rating-announces-price-target-of-4

Stifel analyst Laura Prendergast initiates coverage on Erasca (NASDAQ:ERAS) with a Buy rating and announces Price Target of $4.

 b-of-a-securities-downgrades-erasca-to-underperform-lowers-price-target-to-1

B of A Securities analyst Alec Stranahan downgrades Erasca (NASDAQ:ERAS) from Buy to Underperform and lowers the price targe...

 morgan-stanley-downgrades-erasca-to-equal-weight-lowers-price-target-to-2

Morgan Stanley analyst Jeffrey Hung downgrades Erasca (NASDAQ:ERAS) from Overweight to Equal-Weight and lowers the price tar...

 erasca-files-for-mixed-shelf-of-up-to-500m-sale-agreement-prospectus-covering-offering-of-up-200m-common-stock-that-may-be-issued-under-sale-agreement

-SEC Filing

 erasca-q2-eps-012-misses-011-estimate

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9...

 erasca-secures-fda-clearance-for-first-in-class-pan-kras-inhibitor-eras-4001

Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guid...

 erasca-q1-eps-011-beats-012-estimate

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.3...

 hc-wainwright--co-reiterates-buy-on-erasca-maintains-6-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca (NASDAQ:ERAS) with a Buy and maintains $6 price target.

 erasca-presents-new-preclinical-data-for-profiles-of-ras-targeting-franchise-at-2025-aacr-annual-meeting

ERAS-0015 and ERAS-4001 showed robust anti-tumor activity as monotherapy and combination therapyFirst-in-class examples of dire...

 raymond-james-initiates-coverage-on-erasca-with-outperform-rating-announces-price-target-of-5

Raymond James analyst Laura Prendergast initiates coverage on Erasca (NASDAQ:ERAS) with a Outperform rating and announces Pr...

 goldman-sachs-maintains-buy-on-erasca-lowers-price-target-to-3

Goldman Sachs analyst Chris Shibutani maintains Erasca (NASDAQ:ERAS) with a Buy and lowers the price target from $3.5 to $3.

 hc-wainwright--co-reiterates-buy-on-erasca-maintains-6-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca (NASDAQ:ERAS) with a Buy and maintains $6 price target.

 erasca-q4-2024-gaap-eps-011-beats-012-estimate

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.3...

 morgan-stanley-assumes-erasca-at-overweight-maintains-price-target-of-4

Morgan Stanley analyst Jeffrey Hung assumes Erasca (NASDAQ:ERAS) with a Overweight rating and maintains Price Target of $4.

 b-of-a-securities-upgrades-erasca-to-buy-maintains-price-target-to-5

B of A Securities analyst Alec Stranahan upgrades Erasca (NASDAQ:ERAS) from Neutral to Buy and maintains the price target fr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION